CXCL-10: a new candidate for melanoma therapy?

ConclusionsRecent studies indicate that the CXCL10/CXCR3 axis may act as a double-edged sword in terms of pro- and anti-cancer activities in a variety of tissues and cells, especially in melanoma cells and their microenvironments. Most of these activities arise from the CXCR3 splice variants CXCR3-A, CXCR3-B and CXCR3-Alt. In this review, we discuss the pro- and anti-cancer properties of CXCL10 in various types of tissues and cells, particularly melanoma cells, including its potential as a therapeutic target.

http://link.springer.com/10.1007/s13402-020-00501-z

Source: Cellular Oncology - March 22, 2020 Category: Cancer & Oncology Source Type: research